Skip to Content

Istodax (romidepsin) Disease Interactions

There are 5 disease interactions with Istodax (romidepsin):

Moderate

Romidepsin (Includes Istodax) ↔ hepatic impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Romidepsin population pharmacokinetic analysis indicated that mild hepatic impairment had no significant influence on romidepsin pharmacokinetics. Care and close monitoring of liver function is recommended in patients with moderate and severe hepatic impairment as the pharmacokinetics of romidepsin is unknown in these patients.

Moderate

Romidepsin (Includes Istodax) ↔ infections

Moderate Potential Hazard, Moderate plausibility. Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Cases of fatal and serious infections, including pneumonia, sepsis, and viral reactivation, including Epstein Barr and hepatitis B viruses have been reported with the use of romidepsin. The risk of life threatening infections may be greater in patients with a history of prior treatment with monoclonal antibodies directed against lymphocyte antigens and in patients with disease involvement of the bone marrow. Monitor reactivation in patients with evidence of prior hepatitis B infection as recommended and consider antiviral prophylaxis as clinically indicated.

Moderate

Romidepsin (Includes Istodax) ↔ myelosuppression

Moderate Potential Hazard, Moderate plausibility. Applies to: Neutropenia, Thrombocytopenia, Lymphocytopenia

The use of romidepsin may cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and anemia. It is recommended to monitor blood counts regularly during treatment, and if necessary to modify the dose of romidepsin according to clinical practices.

Moderate

Romidepsin (Includes Istodax) ↔ QT prolongation

Moderate Potential Hazard, Moderate plausibility. Applies to: Arrhythmias, Cardiovascular Disease

The use of romidepsin may cause changes in ECG. It is recommended to consider cardiovascular monitoring of ECG prior to starting therapy and periodically during treatment in patients with congenital long QT syndrome, history of significant cardiovascular disease, and in patients taking anti-arrhythmic medicines or medicinal products that lead to significant QT prolongation. Confirm that potassium and magnesium levels are within normal range before administration of romidepsin. Care and close monitoring is recommended.

Moderate

Romidepsin (Includes Istodax) ↔ renal impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

Romidepsin population pharmacokinetic analysis indicated that romidepsin pharmacokinetics were not affected by renal impairment. Care and close monitoring is recommended when prescribing this agent to patients with end-stage renal disease as the pharmacokinetics of romidepsin have not been studied in these patients.

Istodax (romidepsin) drug interactions

There are 496 drug interactions with Istodax (romidepsin)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide